Yang R, Fei L, Xue Y, Zhang Y, Hu Q, Guo L
J Cell Mol Med. 2025; 29(5):e70384.
PMID: 40070134
PMC: 11897054.
DOI: 10.1111/jcmm.70384.
Wang Y, Allen I, Funingana G, Tischkowitz M, Joko-Fru Y
BJC Rep. 2025; 3(1):14.
PMID: 40069561
PMC: 11897386.
DOI: 10.1038/s44276-025-00122-9.
Hohmann L, Sigurjonsdottir K, Campos A, Nacer D, Veerla S, Rosengren F
Nat Commun. 2025; 16(1):2208.
PMID: 40044693
PMC: 11882987.
DOI: 10.1038/s41467-025-57419-z.
Moser S, Jonkers J
Cancer Discov. 2025; 15(3):461-480.
PMID: 40025950
PMC: 11893084.
DOI: 10.1158/2159-8290.CD-24-1326.
Inglebert M, Dettwiler M, He C, Markkanen E, Opitz L, Naguleswaran A
Vet Sci. 2025; 12(2).
PMID: 40005944
PMC: 11861728.
DOI: 10.3390/vetsci12020183.
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics.
Witz A, Dardare J, Betz M, Michel C, Husson M, Gilson P
Biomark Res. 2025; 13(1):31.
PMID: 39985088
PMC: 11846297.
DOI: 10.1186/s40364-025-00740-y.
Genome sequencing enhances the diagnostic yield and expands the genetic landscape of male breast cancer.
Wen W, Zhao S, Jiang Y, Ou C, Guo C, Jia Z
Genet Med Open. 2025; 3:101899.
PMID: 39981113
PMC: 11840214.
DOI: 10.1016/j.gimo.2024.101899.
Anti-PTK7 Monoclonal Antibodies Suppresses Oncogenic Phenotypes in Cellular and Xenograft Models of Triple-Negative Breast Cancer.
Kim M, Park M, Park H, Ham S, Lee H, Lee S
Cells. 2025; 14(3).
PMID: 39936972
PMC: 11817174.
DOI: 10.3390/cells14030181.
Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours.
Ghosh A, Chaubal R, Das C, Parab P, Das S, Maitra A
Commun Biol. 2025; 8(1):207.
PMID: 39930151
PMC: 11811163.
DOI: 10.1038/s42003-025-07606-x.
Subtype-specific role for Jagged1 in promoting or inhibiting breast tumor formation.
Chung W, Wang W, Challagundla L, Moore C, Egan S, Xu K
Oncogenesis. 2025; 14(1):2.
PMID: 39890784
PMC: 11785972.
DOI: 10.1038/s41389-025-00545-6.
Identifying Safeguards Disabled by Epstein-Barr Virus Infections in Genomes From Patients With Breast Cancer: Chromosomal Bioinformatics Analysis.
Friedenson B
JMIRx Med. 2025; 6:e50712.
PMID: 39885374
PMC: 11796484.
DOI: 10.2196/50712.
Multi-omics sequencing of gastroesophageal junction adenocarcinoma reveals prognosis-relevant key factors and a novel immunogenomic classification.
Ma Z, Li M, Li F, Wu K, Wu X, Luo T
Gastric Cancer. 2025; .
PMID: 39883307
DOI: 10.1007/s10120-025-01585-y.
Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction.
Kilim O, Olar A, Biricz A, Madaras L, Pollner P, Szallasi Z
NPJ Precis Oncol. 2025; 9(1):27.
PMID: 39863682
PMC: 11762732.
DOI: 10.1038/s41698-025-00808-w.
Genetic and epigenetic alterations in night shift nurses with breast cancer: a narrative review.
Li X, Hu Y, Aslanbeigi F
Cancer Cell Int. 2025; 25(1):20.
PMID: 39833897
PMC: 11749300.
DOI: 10.1186/s12935-025-03649-6.
CD4FOXP3Exon2 regulatory T cell frequency predicts breast cancer prognosis and survival.
Fusco C, Di Rella F, Liotti A, Colamatteo A, Ferrara A, Gigantino V
Sci Adv. 2025; 11(3):eadr7934.
PMID: 39813341
PMC: 11734725.
DOI: 10.1126/sciadv.adr7934.
Complex rearrangements fuel ER and HER2 breast tumours.
Houlahan K, Mangiante L, Sotomayor-Vivas C, Adimoelja A, Park S, Khan A
Nature. 2025; 638(8050):510-518.
PMID: 39779850
PMC: 11821522.
DOI: 10.1038/s41586-024-08377-x.
Saturation genome editing-based clinical classification of BRCA2 variants.
Sahu S, Galloux M, Southon E, Caylor D, Sullivan T, Arnaudi M
Nature. 2025; 638(8050):538-545.
PMID: 39779848
DOI: 10.1038/s41586-024-08349-1.
The impact of ferroptosis and ferroptosis-related non-coding RNAs on breast cancer progression.
Liu W, Jiang C, Ma Y, Wang W, Peng J, Ma W
Front Cell Dev Biol. 2025; 12:1506492.
PMID: 39763590
PMC: 11701165.
DOI: 10.3389/fcell.2024.1506492.
Mechanisms of tandem duplication in the cancer genome.
Scully R, Glodzik D, Menghi F, Liu E, Zhang C
DNA Repair (Amst). 2025; 145:103802.
PMID: 39742573
PMC: 11843477.
DOI: 10.1016/j.dnarep.2024.103802.
Misclassification of second primary and recurrent breast cancer in the surveillance epidemiology and end results registry.
Van Alsten S, Zipple I, Calhoun B, Troester M
Cancer Causes Control. 2024; .
PMID: 39702817
DOI: 10.1007/s10552-024-01944-7.